RHO — Rhodopsin

The RHO gene provides the essential instructions for making a protein called rhodopsin. Rhodopsin is found exclusively in the retina, the light-sensitive tissue at the back of the eye, specifically within specialized cells called rod photoreceptors. These rod cells are responsible for our ability to see in low-light conditions, such as at night or in dimly lit rooms, and they also provide our peripheral (side) vision. When light enters the eye and strikes the rhodopsin protein, it triggers a complex chain reaction that sends an electrical signal to the brain, allowing us to perceive the image. When there is a mutation or error in the RHO gene, it produces an abnormal rhodopsin protein. Because rhodopsin is so critical to the structure and function of rod cells, the abnormal protein can be toxic or fail to work properly. This leads to the gradual damage and death of the rod photoreceptors. As the rod cells die, patients first experience night blindness (nyctalopia) and a progressive loss of their peripheral vision, often described as developing "tunnel vision." Over time, the disease can also affect the cone photoreceptors, which are responsible for central vision and color perception, eventually leading to severe visual impairment or legal blindness. This condition is known as retinitis pigmentosa (RP). For patients and families, a mutation in the RHO gene typically causes an inherited condition called autosomal dominant retinitis pigmentosa. "Autosomal dominant" means that a person only needs to inherit one copy of the mutated gene from one parent to develop the disease. Consequently, an affected individual has a 50% chance of passing the mutated gene to each of their children. The severity of the vision loss and the age at which symptoms begin can vary widely, even among family members with the exact same mutation. While some individuals may experience rapid vision loss early in life, others may retain useful central vision for many decades. Genetic testing and counseling are important steps for families to understand their specific risks and to stay informed about emerging treatments.

Gene description: Encodes rhodopsin, a light-sensitive receptor protein crucial for vision in dim light.

Patient and family guide: The RHO gene provides the essential instructions for making a protein called rhodopsin. Rhodopsin is found exclusively in the retina, the light-sensitive tissue at the back of the eye, specifically within specialized cells called rod photoreceptors. These rod cells are responsible for our ability to see in low-light conditions, such as at night or in dimly lit rooms, and they also provide our peripheral (side) vision. When light enters the eye and strikes the rhodopsin protein, it triggers a complex chain reaction that sends an electrical signal to the brain, allowing us to perceive the image. When there is a mutation or error in the RHO gene, it produces an abnormal rhodopsin protein. Because rhodopsin is so critical to the structure and function of rod cells, the abnormal protein can be toxic or fail to work properly. This leads to the gradual damage and death of the rod photoreceptors. As the rod cells die, patients first experience night blindness (nyctalopia) and a progressive loss of their peripheral vision, often described as developing "tunnel vision." Over time, the disease can also affect the cone photoreceptors, which are responsible for central vision and color perception, eventually leading to severe visual impairment or legal blindness. This condition is known as retinitis pigmentosa (RP). For patients and families, a mutation in the RHO gene typically causes an inherited condition called autosomal dominant retinitis pigmentosa. "Autosomal dominant" means that a person only needs to inherit one copy of the mutated gene from one parent to develop the disease. Consequently, an affected individual has a 50% chance of passing the mutated gene to each of their children. The severity of the vision loss and the age at which symptoms begin can vary widely, even among family members with the exact same mutation. While some individuals may experience rapid vision loss early in life, others may retain useful central vision for many decades. Genetic testing and counseling are important steps for families to understand their specific risks and to stay informed about emerging treatments.

Gene function: RHO is a G protein-coupled receptor found in rod photoreceptor cells. It initiates the phototransduction cascade upon light absorption, converting light signals into electrical impulses that are sent to the brain, enabling scotopic (dim light) vision.

Protein structure: The RHO gene encodes rhodopsin, a 348-amino acid protein with a molecular weight of approximately 39 kDa. Rhodopsin is a prototypical member of the Class A (rhodopsin-like) family of G protein-coupled receptors (GPCRs). Its structure is characterized by seven hydrophobic alpha-helical transmembrane domains that span the lipid bilayer of the rod outer segment disc membranes. These transmembrane helices are connected by three extracellular (intradiscal) loops and three intracellular (cytoplasmic) loops. The N-terminus of the protein is located within the intradiscal space, while the C-terminus extends into the cytoplasm. The structural integrity and function of rhodopsin rely on several critical features and post-translational modifications. A highly conserved lysine residue (Lys296) located in the seventh transmembrane helix serves as the attachment site for the light-sensitive chromophore, 11-cis-retinal, via a protonated Schiff base linkage. The intradiscal domain contains a crucial disulfide bond between Cys110 and Cys187, which is essential for proper protein folding and stability. Additionally, the N-terminus undergoes glycosylation at Asn2 and Asn15, which aids in the correct routing of the protein to the outer segment. The cytoplasmic C-terminal tail contains multiple serine and threonine residues that are phosphorylated by rhodopsin kinase following light activation, a modification necessary for the binding of arrestin and the subsequent deactivation of the signaling cascade. Rhodopsin functions as a monomeric receptor, though it is densely packed within the disc membranes to optimize photon capture.

Molecular function: The RHO gene encodes rhodopsin, the highly specialized G protein-coupled receptor (GPCR) responsible for mediating the first step of the visual phototransduction cascade in rod photoreceptor cells. Rhodopsin is exquisitely sensitive to light, enabling image-forming vision in scotopic (low-light) conditions. The functional rhodopsin molecule consists of the opsin apoprotein covalently linked to a light-sensitive chromophore, 11-cis-retinal, via a Schiff base linkage at a specific lysine residue (Lys296). In its dark-adapted state, rhodopsin is inactive. When a photon of light strikes the molecule, it triggers the rapid photoisomerization of 11-cis-retinal to its all-trans-retinal conformation. This photoisomerization induces a series of conformational changes in the opsin protein, culminating in the formation of the active intermediate, metarhodopsin II. Metarhodopsin II then binds to and activates the heterotrimeric G-protein transducin (Gt). The activated alpha subunit of transducin exchanges GDP for GTP and subsequently activates cyclic GMP (cGMP) phosphodiesterase (PDE6). The activated PDE6 rapidly hydrolyzes cGMP, leading to a decrease in intracellular cGMP concentration. This reduction causes the closure of cGMP-gated cation channels in the rod outer segment membrane, resulting in cellular hyperpolarization and a decrease in the release of the neurotransmitter glutamate at the synaptic terminal. This change in neurotransmitter release signals the detection of light to downstream retinal neurons. Following activation, the phototransduction cascade must be rapidly terminated to allow the photoreceptor to respond to subsequent light stimuli. This is achieved through the phosphorylation of the activated rhodopsin by rhodopsin kinase (GRK1), which increases its affinity for the inhibitory protein arrestin (SAG). The binding of arrestin sterically blocks further interaction between rhodopsin and transducin, effectively quenching the signal. The all-trans-retinal chromophore is then released from the opsin and transported to the retinal pigment epithelium (RPE) to be enzymatically converted back to 11-cis-retinal through the visual cycle, allowing the regeneration of functional rhodopsin. Beyond its role in signaling, rhodopsin is also a major structural component of the rod outer segment discs, and its proper folding and transport are essential for photoreceptor viability.

Expression pattern: The RHO gene is highly and specifically expressed in the retina, with its expression restricted almost exclusively to rod photoreceptor cells. Within the rod photoreceptor, the rhodopsin protein is synthesized in the inner segment and subsequently transported via the connecting cilium to the outer segment, where it is densely packed into the membranous discs. Rhodopsin is the most abundant protein in the rod outer segment, constituting approximately 80% to 90% of the total protein content in these specialized structures. This massive concentration is essential for maximizing the probability of photon capture in low-light environments. Developmentally, the expression of the RHO gene is tightly regulated and coincides with the differentiation and maturation of rod photoreceptors. In humans, rhodopsin expression begins during fetal development and continues throughout life, playing a critical role not only in visual transduction but also in the structural maintenance and viability of the rod outer segments. The precise targeting and high-level expression of rhodopsin are governed by specific promoter and enhancer elements that interact with retinal transcription factors, such as NRL and CRX. There are no known tissue-specific isoforms of rhodopsin outside the retina, underscoring its highly specialized role in the visual system.

Mutation spectrum: The mutation spectrum of the RHO gene is extensive and diverse, with over 290 distinct pathogenic variants identified to date. The vast majority of these mutations are associated with autosomal dominant retinitis pigmentosa (adRP), making RHO the most frequently mutated gene in this condition. The mutation spectrum is predominantly composed of missense mutations, which account for the majority of cases and typically result in single amino acid substitutions that disrupt protein folding, stability, or function. Other types of mutations, including nonsense mutations, small deletions, insertions, frameshifts, and splice-site variants, are also observed but are less common. Mutations are distributed throughout the entire RHO gene, affecting various structural and functional domains of the rhodopsin protein, including the intradiscal, transmembrane, and cytoplasmic regions. However, certain regions are considered mutation hotspots. For example, the intradiscal domain, which is critical for proper protein folding and disulfide bond formation, harbors numerous pathogenic variants. Founder mutations have also been identified in specific populations; notably, the p.Pro23His mutation is a well-known founder mutation that accounts for a significant proportion of RHO-adRP cases in the United States, while other specific variants may be more prevalent in European or Asian populations. The wide variety of mutations contributes to the significant clinical heterogeneity observed in RHO-associated retinal dystrophies.

Pathogenic variants: 1. p.Pro23His (c.68C>A) - The most common RHO mutation in North America, acting as a founder mutation. It is a Class 2 mutation causing protein misfolding and ER retention, typically resulting in a classic, progressive generalized retinitis pigmentosa phenotype. 2. p.Pro347Leu (c.1040C>T) - A frequent Class 1 mutation affecting the C-terminal sorting signal, disrupting the transport of rhodopsin to the outer segment. It is generally associated with an early-onset, severe form of generalized retinitis pigmentosa. 3. p.Thr58Arg (c.173C>G) - A well-characterized mutation frequently associated with the sector retinitis pigmentosa phenotype. Patients typically exhibit localized retinal degeneration, often in the inferior retina, with a later onset and slower progression of visual loss. 4. p.Arg135Trp (c.403C>T) - A common and severe missense mutation located at the cytoplasmic border of the third transmembrane helix. It is associated with classic autosomal dominant retinitis pigmentosa and significant visual impairment. 5. p.Asp190Asn (c.568G>A) - A pathogenic variant that can present with classic signs of retinitis pigmentosa but is sometimes associated with a milder phenotype where patients may maintain good central visual acuity into adulthood.

Clinical significance: Mutations in the RHO gene are the most common cause of autosomal dominant retinitis pigmentosa (adRP), accounting for approximately 25% to 30% of all adRP cases. The clinical manifestation of RHO-associated adRP typically begins with nyctalopia (night blindness) in adolescence or early adulthood, reflecting the primary dysfunction and degeneration of rod photoreceptors. As the disease progresses, patients experience a gradual constriction of their peripheral visual field, often described as "tunnel vision." In the later stages of the disease, secondary degeneration of cone photoreceptors occurs, leading to the loss of central vision, decreased visual acuity, and impaired color perception. The severity and rate of progression can vary significantly among individuals, even within the same family, but it generally leads to severe visual impairment or legal blindness by middle age. The clinical presentation of RHO-associated RP can be broadly categorized into two main phenotypes: generalized (or classic) RP and sector RP. Generalized RP is characterized by widespread retinal involvement, early onset of symptoms, and a more rapid progression of visual loss. Fundus examination typically reveals classic signs such as bone-spicule pigmentation, optic disc pallor, and attenuation of retinal blood vessels throughout the retina. In contrast, sector RP is a milder and more localized form of the disease, where retinal degeneration and pigmentary changes are confined to specific regions, most commonly the inferior retina. Patients with sector RP often have a later onset of symptoms, slower disease progression, and may retain good central vision for a longer period. Rarely, RHO mutations have also been associated with autosomal recessive retinitis pigmentosa (arRP) and congenital stationary night blindness (CSNB), which present with distinct clinical features and inheritance patterns.

Inheritance: Autosomal dominant, autosomal recessive

Chromosomal location: 3q22.1

Genotype-phenotype correlations: Genotype-phenotype correlations in RHO-associated retinitis pigmentosa are well-documented and provide valuable prognostic information. The specific location and nature of the RHO mutation strongly influence the clinical presentation, severity, and progression of the disease. Mutations are often classified based on their biochemical and cellular effects. For instance, Class 1 mutations, which primarily affect the post-Golgi trafficking and targeting of rhodopsin to the outer segment, are generally associated with a more severe, generalized RP phenotype. Patients with these mutations typically experience an earlier onset of nyctalopia, more rapid visual field constriction, and worse baseline visual acuity. Conversely, Class 2 mutations, which cause protein misfolding and retention in the endoplasmic reticulum, exhibit a wider range of phenotypic severity. While some Class 2 mutations cause severe generalized RP, others are associated with the milder sector RP phenotype. For example, the p.Pro23His mutation, a common Class 2 variant in North America, often presents with a classic, progressive RP phenotype. In contrast, mutations such as p.Thr58Arg are frequently associated with sector RP, characterized by localized retinal degeneration (often inferiorly), later onset of symptoms, and a slower rate of visual decline. The regional specificity in sector RP is hypothesized to be related to light exposure, as the inferior retina receives more light from the superior visual field, potentially exacerbating the toxic effects of certain misfolded rhodopsin variants.

Research and therapeutic approaches: Currently, there are no FDA-approved curative therapies specifically for RHO-associated retinitis pigmentosa, and clinical management primarily focuses on supportive care, such as low-vision aids, mobility training, and genetic counseling. Vitamin A palmitate supplementation has been historically suggested to slightly slow the decline of retinal function in some RP patients, but its efficacy is debated and it must be monitored carefully due to potential liver toxicity. However, the landscape of therapeutic approaches is rapidly evolving, with several promising strategies in preclinical and clinical development aimed at preserving vision or restoring function. Gene therapy is a major focus of research for RHO-adRP. Because the disease is primarily caused by dominant-negative or toxic gain-of-function mutations, traditional gene augmentation (simply adding a healthy copy of the gene, as is done with Luxturna for RPE65 mutations) is generally insufficient. Instead, "knock-and-replace" strategies are being developed. These approaches use viral vectors (like AAV) to deliver agents such as CRISPR/Cas9 or short hairpin RNAs (shRNAs) to knock down the expression of both the mutant and wild-type endogenous RHO alleles, while simultaneously delivering a hardened, wild-type RHO gene that is resistant to the knockdown mechanism. Other advanced genetic therapies include the use of antisense oligonucleotides (ASOs), such as QR-1123 (NCT04123626), which are designed to specifically bind to and degrade the mutant RHO mRNA (e.g., targeting the P23H mutation) while sparing the normal transcript. Additionally, pharmacological approaches using small molecule chaperones are being investigated to correct the misfolding of mutant rhodopsin proteins, thereby reducing endoplasmic reticulum stress and preventing photoreceptor apoptosis.

Diagnostic testing: Diagnostic testing for RHO-associated retinitis pigmentosa typically involves comprehensive ophthalmic evaluation combined with molecular genetic testing. Clinical diagnosis is based on a detailed patient history, visual acuity and visual field testing, and fundus examination revealing characteristic pigmentary changes. Electroretinography (ERG) is crucial for assessing photoreceptor function, typically showing reduced or absent rod responses early in the disease, followed by declining cone responses. High-resolution imaging techniques, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF), are used to evaluate retinal structural changes, monitor disease progression, and identify specific phenotypic patterns, such as sector versus generalized RP. Molecular genetic testing is essential to confirm the diagnosis and determine the specific genetic etiology. This is most commonly achieved through targeted next-generation sequencing (NGS) panels that include RHO and other genes known to cause inherited retinal dystrophies. In cases where panel testing is inconclusive, whole exome sequencing (WES) or whole genome sequencing (WGS) may be employed. Genetic counseling is a critical component of the diagnostic process, providing patients and families with information about the autosomal dominant inheritance pattern, the risk of transmission to offspring (typically 50% for each child of an affected individual), and the variable expressivity of the disease. Identifying the specific RHO mutation is also increasingly important for determining eligibility for emerging gene-specific clinical trials and targeted therapies.

Animal models: Animal models have been instrumental in elucidating the pathophysiology of RHO-associated retinitis pigmentosa and testing potential therapies. The Rho knockout mouse model (Rho-/-) is a classic model that demonstrates the necessity of rhodopsin for rod photoreceptor outer segment formation and cell survival, as these mice fail to develop proper outer segments and undergo rapid rod degeneration followed by secondary cone loss. Knock-in mouse models expressing specific human mutations, such as the P23H and T58R variants, have been developed to study the dominant-negative and toxic gain-of-function effects of misfolded rhodopsin. These models accurately recapitulate the human disease phenotype, including progressive photoreceptor apoptosis and retinal thinning. In addition to murine models, zebrafish and canine models have provided valuable insights. Zebrafish models, generated via CRISPR/Cas9 or transgenic approaches, are particularly useful for studying the developmental aspects of rod genesis and the effects of rhodopsin mutations on outer segment disc formation. They offer the advantage of rapid development and large clutch sizes for high-throughput screening of pharmacological agents. Canine models, such as the naturally occurring English Mastiff model with a rhodopsin mutation, provide a large animal system with an eye size and structure more similar to humans, making them crucial for evaluating the safety, efficacy, and surgical delivery techniques of gene therapies prior to human clinical trials.

Population genetics: The population genetics of RHO mutations are characterized by significant geographic and ethnic variability. While RHO mutations are the most common cause of autosomal dominant retinitis pigmentosa (adRP) globally, accounting for roughly 25-30% of cases, the prevalence of specific variants differs markedly between populations. In the United States, the p.Pro23His mutation is exceptionally prevalent, accounting for approximately 10% of all adRP cases, largely due to a founder effect originating from a common ancestor of British descent. In contrast, this specific mutation is rare in European and Asian populations. Other variants, such as p.Pro347Leu, have a more global distribution but still exhibit varying frequencies across different ethnic groups. Because RHO-associated RP is predominantly an autosomal dominant condition, the concept of a "carrier frequency" in the traditional sense (as used for recessive disorders) is less applicable, as individuals harboring a single pathogenic variant typically manifest the disease. However, the overall genetic prevalence of RHO mutations reflects the incidence of adRP in the general population, which is estimated to be around 1 in 3,000 to 4,000 individuals worldwide.

Selected references: 1. Daich Varela M, et al. RHO-Associated Retinitis Pigmentosa: Genetics, Phenotype, Natural History, Functional Assays, and Animal Model - In Preparation for Clinical Trials. Invest Ophthalmol Vis Sci, 2025. PMID: 40736177 2. Amaral RAS, et al. Expanding the clinical and genetic spectrum of RHO-associated retinitis pigmentosa. Exp Biol Med (Maywood), 2026. PMID: 41716464 3. Athanasiou D, et al. Rescue of mutant rhodopsin trafficking by small molecule correctors. Hum Mol Genet, 2018. PMID: 29346643 4. Meng D, et al. Spectrum-frequency and genotype-phenotype analysis of RHO variants in Chinese patients with retinitis pigmentosa. Exp Eye Res, 2020. PMID: 32882181 5. Vilela MAP, et al. Novel codon 15 RHO gene mutation associated with retinitis pigmentosa. Int J Retina Vitreous, 2018. PMID: 30479854 6. Massengill MT, et al. Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa. Adv Exp Med Biol, 2021. PMID: 34558067 7. Clémençon M, et al. Generation of human P347L RHO-associated retinitis pigmentosa iPSC lines by a mutation insertion in the RHODOPSIN gene carrying the RHO c.1040C > T variant using CRISPR/Cas9. Stem Cell Res, 2026. PMID: 41950725